ProfileGDS5678 / 1453076_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 67% 67% 68% 66% 67% 69% 66% 68% 67% 67% 67% 67% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0516867
GSM967853U87-EV human glioblastoma xenograft - Control 24.0536867
GSM967854U87-EV human glioblastoma xenograft - Control 34.0467667
GSM967855U87-EV human glioblastoma xenograft - Control 44.2104668
GSM967856U87-EV human glioblastoma xenograft - Control 53.9977366
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0649167
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.283469
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.021566
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1336668
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0345867
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0227567
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0243367
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0473867
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0344667